Pharmaceutical Company Zydus Cadilla has sought Drug Controller General of India's(DCGI) approval to undertake clinical trials for monoclonal antibodies cocktail that can neutralise Covid infection. India's leading Indian Pharmaceutical company Zydus Cadilla Healthcare has announced biological therapy ZRC-3308 for the treatment of mild COVID-19 symptoms. ZRC-3308 is a cocktail of two anti-SARS-CoV-2 monoclonal antibodies.
 
Managing Director of Cadila Healthcare Limited, Dr. Sharvil Patel has said that there is a critical need to explore safe and more efficacious treatment to combat Covid at this juncture. He said, it is important to look at different stages of the disease progression and options that can reduce a patient's suffering and discomfort. Mr. Patel believed that ZRC-3308 has the potential to address these concerns and provide safe treatment.